<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Some recent findings suggest that metformin, an oral antidiabetic drug, may have antitumor properties. Studies have shown that metformin can alter cell metabolism, both tumor and immune cells, which can greatly influence disease outcome. In this review, we discuss the potential mechanisms in which metformin can directly induce apoptosis of tumor cells as well as mechanisms in which metformin can elicit or enhance antitumor immune response.</p>
</abstract>

Some recent findings suggest that metformin, an oral antidiabetic drug, may have antitumor properties. Studies have shown that metformin can alter cell metabolism, both tumor and immune cells, which can greatly influence disease outcome. In this review, we discuss the potential mechanisms in which metformin can directly induce apoptosis of tumor cells as well as mechanisms in which metformin can elicit or enhance antitumor immune response.

Metformin as a Potential Antitumor Agent

Department of Surgery, Faculty of Medicine Foca

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

{"article-title":"Metformin as a Potential Antitumor Agent"}

Some recent findings suggest that metformin, an oral antidiabetic drug, may have antitumor properties. Studies have shown that metformin can alter cell...

Metformin as a Potential Antitumor Agent

Publié en ligne: 16 nov. 2022

Pages: -

Reçu: 27 déc. 2021

Accepté: 19 févr. 2022

DOI: https://doi.org/10.2478/sjecr-2022-0023

Mots clés
Metformin, tumor, antitumor immune response

© 2022 Andjela Petrovic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Metformin as a Potential Antitumor Agent

Publié en ligne: 16 nov. 2022

Pages: -

Reçu: 27 déc. 2021

Accepté: 19 févr. 2022

DOI: https://doi.org/10.2478/sjecr-2022-0023

Mots clésMetformin, tumor, antitumor immune response

© 2022 Andjela Petrovic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mots clés
Metformin, tumor, antitumor immune response